InterCure Ltd
TASE:INCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
444
1 254
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InterCure Ltd
Common Shares Outstanding
InterCure Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
I
|
InterCure Ltd
TASE:INCR
|
Common Shares Outstanding
â‚Ş45.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
22%
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Common Shares Outstanding
$1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
||
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Common Shares Outstanding
$27.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
||
Mediwound Ltd
NASDAQ:MDWD
|
Common Shares Outstanding
$9.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
||
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Common Shares Outstanding
â‚Ş34m
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Common Shares Outstanding
â‚Ş11.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
What is InterCure Ltd's Common Shares Outstanding?
Common Shares Outstanding
45.6m
ILS
Based on the financial report for Dec 31, 2023, InterCure Ltd's Common Shares Outstanding amounts to 45.6m ILS.
What is InterCure Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
22%
Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for InterCure Ltd have been 19% over the past three years , -11% over the past five years , and 22% over the past ten years .